Brief: Kura Oncology Receives Breakthrough Therapy Designation For Ziftomenib
22/04/2024 12:36
April 22 (Reuters) - Kura Oncology Inc KURA.O :
* KURA ONCOLOGY RECEIVES BREAKTHROUGH THERAPY DESIGNATION
FOR
ZIFTOMENIB IN NPM1-MUTANT AML
* KURA ONCOLOGY INC - REGISTRATION-DIRECTED TRIAL OF
ZIFTOMENIB IN
NPM1-MUTANT AML ON TRACK TO COMPLETE ENROLLMENT BY MID-2024
Source text for Eikon: ID:nGNX5dx3RK
Further company coverage: KURA.O
((Reuters.Briefs@thomsonreuters.com;))